Activated CD8+ T cells in the tumor and cytotoxic T cell signature correlate with immune response in patients receiving neoadjuvant immunotherapy for treatment of muscle invasive bladder cancer.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bellmunt, J. & Bajorin, D. F. N. Engl. J. Med. 376, 2304 (2017).
Balar, A. V. et al. Lancet Oncol. 18, 1483–1492 (2017).
Mariathasan, S. et al. Nature 554, 544–548 (2018).
Teo, M.Y. et al. J. Clin. Oncol. JCO2017757740 (2018).
Powles, T. et al. https://doi.org/10.1038/s41591-019-0628-7 (2019).
Necchi, A. et al. J. Clin. Oncol. JCO1801148 (2018).
Hoimes, C. J et al. ESMO 2018 Congress, LBA33 (2018).
Huang, A. C. et al. Nat. Med. 25, 454–461 (2019).
Sjödahl, G. et al. Clin. Cancer Res. 18, 3377–3386 (2012).
Ayers, M. et al. J. Clin. Invest. 127, 2930–2940 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Ghatalia, P., Plimack, E. Biomarkers for neoadjuvant checkpoint blockade response in urothelial cancer. Nat Med 25, 1650–1651 (2019). https://doi.org/10.1038/s41591-019-0645-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0645-6
